HealthEquity, Inc. (NASDAQ:HQY - Get Free Report) EVP Elimelech Rosner sold 58,000 shares of the firm's stock in a transaction on Friday, June 6th. The stock was sold at an average price of $112.56, for a total transaction of $6,528,480.00. Following the completion of the sale, the executive vice president now owns 75,689 shares in the company, valued at $8,519,553.84. This represents a 43.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
HealthEquity Price Performance
Shares of NASDAQ HQY traded up $0.77 during trading on Friday, reaching $104.76. The company had a trading volume of 854,492 shares, compared to its average volume of 835,087. HealthEquity, Inc. has a 52 week low of $65.01 and a 52 week high of $116.65. The stock has a market cap of $9.06 billion, a PE ratio of 96.11, a PEG ratio of 1.60 and a beta of 0.49. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.20 and a current ratio of 3.20. The business's 50 day moving average price is $93.96 and its 200-day moving average price is $97.89.
HealthEquity (NASDAQ:HQY - Get Free Report) last announced its earnings results on Tuesday, June 3rd. The company reported $0.97 earnings per share for the quarter, topping analysts' consensus estimates of $0.81 by $0.16. The company had revenue of $330.80 million during the quarter, compared to the consensus estimate of $322.25 million. HealthEquity had a net margin of 8.41% and a return on equity of 9.70%. During the same period in the previous year, the firm posted $0.80 earnings per share. Analysts expect that HealthEquity, Inc. will post 2.32 earnings per share for the current year.
Analyst Upgrades and Downgrades
HQY has been the topic of several recent research reports. Bank of America lifted their target price on shares of HealthEquity from $110.00 to $125.00 and gave the company a "buy" rating in a research report on Wednesday, June 4th. Royal Bank of Canada lifted their target price on shares of HealthEquity from $112.00 to $117.00 and gave the company an "outperform" rating in a research report on Wednesday, June 4th. Raymond James upgraded shares of HealthEquity from an "outperform" rating to a "strong-buy" rating and decreased their target price for the company from $120.00 to $115.00 in a research report on Tuesday, March 25th. KeyCorp decreased their target price on shares of HealthEquity from $110.00 to $100.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 16th. Finally, Wall Street Zen upgraded shares of HealthEquity from a "hold" rating to a "buy" rating in a research report on Friday, June 6th. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $118.09.
Check Out Our Latest Stock Report on HQY
Institutional Investors Weigh In On HealthEquity
Large investors have recently bought and sold shares of the company. Pier Capital LLC bought a new stake in HealthEquity in the fourth quarter valued at approximately $8,024,000. HighTower Advisors LLC increased its stake in HealthEquity by 4.8% in the fourth quarter. HighTower Advisors LLC now owns 95,075 shares of the company's stock valued at $9,122,000 after purchasing an additional 4,370 shares in the last quarter. Wells Fargo & Company MN increased its stake in HealthEquity by 4.7% in the fourth quarter. Wells Fargo & Company MN now owns 124,940 shares of the company's stock valued at $11,988,000 after purchasing an additional 5,594 shares in the last quarter. Geneva Capital Management LLC boosted its holdings in shares of HealthEquity by 24.6% in the fourth quarter. Geneva Capital Management LLC now owns 1,048,903 shares of the company's stock valued at $100,642,000 after buying an additional 206,894 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of HealthEquity by 2.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,086,811 shares of the company's stock valued at $104,280,000 after buying an additional 25,004 shares during the period. Institutional investors own 99.55% of the company's stock.
HealthEquity Company Profile
(
Get Free Report)
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Featured Articles

Before you consider HealthEquity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HealthEquity wasn't on the list.
While HealthEquity currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.